An allosteric SHP2 inhibitor suppresses breast cancer-induced osteoclastogenesis and bone lysis
{{output}}
Inhibition of osteoclast hyperactivation represents a promising therapeutic approach for pathological bone destruction induced by breast cancer bone metastasis. Inhibitors of Src Homology 2 Domain-Containing Protein Tyrosine Phosphatase 2 (SHP2), a protein tyr... ...
